Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Key advances In the SURMOUNT-1 trial for obesity, adults with overweight or obesity without type 2 diabetes mellitus achieved placebo-subtracted weight loss of up to 20% after 72 weeks of the GLP1GIP receptor co-agonist tirzepatide, with a similar safety profile to high-dose semaglutide 5
wk, week
However, this effectiveness comes with an exorbitant cost, with the retail price of these medications over $1000 per month [36] [37]
This medication represents an important therapy option for metabolic disease due to its dual incretin receptor activation
US$ 22.78
US$ 26.28
US$ 25.83
US$ 20.10
US$ 23.23
US$ 25.71
US$ 29.55
